Main Process

  • Collection of whole blood from patient (for autologous) or healthy donor (for allogenic)
  • Isolation of immune cell from the blood using semi-automated and fully closed cell isolation process
  • Activation of isolated immune cells are with ancillary protein class I developed by GI Cell, Inc.
  • Expansion of the immune cells with ancillary protein class II developed by GI Cell, Inc.
  • Infusion of the processed specific-immune cells into the patient's bloodstream to treat a disease

T.O.P. NK®


Key features of T.O.P. NK®

  • Tumor-targeting Optimally Primed (T.O.P.) NK Cell.
  • T.O.P. NK cells are robustly activated and amplified using ONLY the ancillary proteins in the NKPURE Expander® platform.
  • T.O.P. NK cells are highly pure (>99%) and safe to use as NO feeder cells are used during the cultivation process.
  • Even with NO genetic modification or viral transduction, CD16 (FcγRIII) expression and cytotoxic granule contents are HIGHLY ELEVATED in T.O.P NK cells.
  • High CD16 expression enables T.O.P. NK cells to target and kill tumor cells via antibody-dependent cell cytotoxicity (ADCC).
  • Robust cytotoxic granule contents elevate T.O.P. NK cells’ killing competency.

Nano NK®


Key features of Nano NK®

  • Nanoparticle-armed (Nano) NK Cells are NK cells carrying pH-sensitive nanoparticles loaded with a chemotherapeutic drug.
  • Tumor-specific homing and targeting by the NK cells grants major advantages over conventional chemotherapy, which causes systemic adverse effect to the recipients.
  • Nano NK cells carry out tumor-targeted drug delivery, which significantly reduce the toxicity of released chemotherapeutic agent.
  • Upon engaging a tumor cell, Nano NK cell releases its cytotoxic granules, causing the immunological synapse between engaging NK cell and target tumor cell to turn acidic.
  • Acidification of the surroundings prompts nanoparticle disassembly and release of chemotherapeutic drug directly onto the tumor cell, resulting in tumor cell killing.
  • This technology could also be adapted to reinforce cytotoxic T lymphocytes with chemo-loaded nanoparticles.

X-Pres T CELL®


Key features of X-Pres T CELL®

  • Personalized, tumor-targeting autologous cytotoxic T lymphocytes for cancer treatment.
  • Personalized tumor antigen profiling is performed to identify target antigens.
  • Matching target antigens are selected from the GI Cell’s “in-house engineered” tumor antigen library.
  • Through a process called “cross-presentation,” CTLs are selectively educated to eliminate cancer cells expressing the target antigens.
  • Educated tumor-specific CTLs (X-Pres T CELL®) are further amplified and activated using GI Cell’s ancillary proteins.
  • The cultivation process with GI Cell’s ancillary proteins increases purity of X-Pres T CELL®, eliminating the need for further (and expensive) cell purification steps.
  • X-Pres T CELL® are administered to the patient as treatment for cancer.

Drone Treg®


Key features of Drone Treg®

  • Regulatory T cells play important role in maintaining tolerance and immune cell homeostasis.
  • Tregs are crucial in controlling chronic inflammatory diseases as they can suppress inflammatory immune responses through secretion of inhibitory cytokines.
  • Target organ-specific regulatory T cell therapy platform which induces controlled expression of organ-specific homing receptors from the Foxp3hi regulatory T cell isolated from patient’s blood.
  • Drone Treg® expressing gut-specific homing markers, CCR9 and α4β7 integrin, induce migration to lesion of patient’s gut after infusion.
  • In intestinal autoimmune diseases, APCs and effector T cells elicit and propagate aberrant inflammatory responses towards innocuous antigens, such as food particles or commensal microbiomes, which leads to tissues damage in the gut.
  • Drone Treg® in the gut can effectively control the inflammatory APCs and effector T cells by releasing anti-inflammatory cytokines and induce repair of damaged tissues.